References
- 1. M. S. Kim, C. W. Lee, J. H. Kim, J. C. Lee and W. G. An, Extract of rhus verniciflua stokes induces p53-mediated apoptosis in MCF-7 breast cancer cells, Evid. Based Complement. Alternat. Med. 2019 (2019) Article ID 9407340 (10 pages); https://doi.org/10.1155/2019/9407340638342730881477
- 2. H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal and F. Bray, Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin. 71(3) (2021) 209–249; https://doi.org/10.3322/caac.2166033538338
- 3. R. Venkatadri, T. Muni, A. K. Iyer, J. S. Yakisich and N. Azad, Role of apoptosis-related miRNAs in resveratrol-induced breast cancer cell death, Cell Death Dis. 7 (2016) e2104; (12 pages) https://doi.org/10.1038/cddis.2016.6539919426890143
- 4. C. A. Dehelean, I. Marcovici, C. Soica, M. Mioc, D. Coricovac, S. Iurciuc, O. M. Cretu and I. Pinzaru, Plant-derived anticancer compounds as new perspectives in drug discovery and alternative therapy, Molecules 26 (2021) Article ID 1109 (29 pages); https://doi.org/10.3390/molecules26041109792218033669817
- 5. V. Singh, K. Kumar, D. Purohit, R. Verma, P. Pandey, S. Bhatia, V. Malik, V. Mittal, M. H. Rahman, G. M. Albadrani, M. W. Arafah, F. M. El-Demerdash, M. F. Akhtar, A. Saleem, M. Kamel, A. Najda, M. M. Abdel-Daim and D. Kaushik, Exploration of therapeutic applicability and different signaling mechanism of various phytopharmacological agents for treatment of breast cancer, Biomed. Pharmacother. 139 (2021) Article ID 111584 (19 pages); https://doi.org/10.1016/j.biopha.2021.11158434243623
- 6. V. M. Dan, R. S. Raveendran and S. Baby, Resistance to intervention: paclitaxel in breast cancer, Mini Rev. Med. Chem. 21 (2021) 1237–1268; https://doi.org/10.2174/138955752099920121423442133319669
- 7. S. Qi, Y. Xin, Y. Guo, Y. Diao, X. Kou, L. Luo and Z. Yin, Ampelopsin reduces endotoxic inflammation via repressing ROS-mediated activation of PI3K/Akt/NF-κB signaling pathways, Int. Immunopharmacol. 12(1) (2012) 278–287; https://doi.org/10.1016/j.intimp.2011.12.00122193240
- 8. V. N. Truong, Y. T. Nguyen and S. K. Cho, Ampelopsin suppresses stem cell properties accompanied by attenuation of oxidative phosphorylation in chemo- and radio-resistant MDA-MB-231 breast cancer cells, Pharmaceuticals (Basel) 14 (2021) Article ID 794 (17 pages); https://doi.org/10.3390/ph14080794840066534451892
- 9. X. Kou, J. Fan and N. Chen, Potential molecular targets of ampelopsin in prevention and treatment of cancers, Anticancer Agents Med. Chem. 17(12) (2017) 1610–1616; https://doi.org/10.2174/187152140966617041213052928403777
- 10. H. Chang, X. Peng, Q. Bai, Y. Zhou, X. Yu, Q. Zhang, J. Zhu and M. Mi, Ampelopsin suppresses breast carcinogenesis by inhibiting the mTOR signalling pathway, Carcinogenesis 35(8) (2014) 1847–1854; https://doi.org/10.1093/carcin/bgu11824861637
- 11. T. Otto and P. Sicinski, Cell cycle proteins as promising targets in cancer therapy, Nat. Rev. Cancer 17 (2017) 93–115; https://doi.org/10.1038/nrc.2016.138534593328127048
- 12. J. C. Bendell, J. Rodon, H. A. Burris, M. de Jonge, J. Verweij, D. Birle, D. Demanse, S. S. De Buck, Q. C. Ru, M. Peters, M. Goldbrunner and J. Baselga, Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors, J. Clin. Oncol. 30(3) (2012) 282–290; https://doi.org/10.1200/JCO.2011.36.136022162589
- 13. D. Gong and J. E. Jr. Ferrell, The roles of cyclin A2, B1 and B2 in early and late mitotic events, Mol. Biol. Cell 21(18) (2010) 3149–3161; https://doi.org/10.1091/mbc.E10-05-0393293838120660152
- 14. F. Fei, J. Qu, K. Liu, C. Li, X. Wang, Y. Li and S. Zhang, The subcellular location of cyclin B1 and CDC25 associated with the formation of polyploid giant cancer cells and their clinicopathological significance, Lab. Invest. 99 (2019) 483–498; https://doi.org/10.1038/s41374-018-0157-x30487595
- 15. T. K. Fung, H. T. Ma and R. Y. Poon, Specialized roles of the two mitotic cyclins in somatic cells: cyclin A as an activator of M phase-promoting factor, Mol. Biol. Cell 18(5) (2007) 1861–1873; https://doi.org/10.1091/mbc.e06-12-1092185502317344473
- 16. Y. Lu, G. Yang, Y. Xiao, T. Zhang, F. Su, R. Chang, X. Ling and Y. Bai, Upregulated cyclins may be novel genes for triple-negative breast cancer based on bioinformatic analysis, Breast Cancer 27 (2020) 903–911; https://doi.org/10.1007/s12282-020-01086-z32338339
- 17. B. Li, H. B. Zhu, G. D. Song, J. H. Cheng, C. Z. Li, Y. Z. Zhang and P. Zhao, Regulating the CCNB1 gene can affect cell proliferation and apoptosis in pituitary adenomas and activate epithelial-tomesenchymal transition, Oncol. Lett. 18(5) (2019) 4651–4658; https://doi.org/10.3892/ol.2019.10847678151831611974
- 18. J. A. Engelman, J. Luo and L. C. Cantley, The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism, Nat. Rev. Genet. 7 (2006) 606–619; https://doi.org/10.1038/nrg187916847462
- 19. A. Ghoneum and N. Said, PI3K-AKT-mTOR and NFκB pathways in ovarian cancer: implications for targeted therapeutics, Cancers 11 (2019) Article ID 949 (26 pages); https://doi.org/10.3390/cancers11070949667909531284467
- 20. B. Zhang, Z. Zhao, X. Meng, H. Chen, G. Fu and K. Xie, Hydrogen ameliorates oxidative stress via PI3K-Akt signaling pathway in UVB-induced HaCaT cells, Int. J. Mol. Med. 41(6) (2018) 3653–3661; https://doi.org/10.3892/ijmm.2018.355029532858
- 21. E. Paplomata and R. O’Regan, The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers, Ther. Adv. Med. Oncol. 6(4) (2014) 154–166; https://doi.org/10.1177/1758834014530023410771225057302
- 22. D. Miricescu, A. Totan, I. I. Stanescu-Spinu, S. C. Badoiu, C. Stefani and M. Greabu, PI3K/AKT/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects, Int. J. Mol. Sci. 22(1) (2020) Article ID 173 (24 pages); https://doi.org/10.3390/ijms22010173779601733375317
- 23. S. Aggarwal, S. John, L. Sapra, S. C. Sharma and S. N. Das, Targeted disruption of PI3K/Akt/mTOR signaling pathway, via PI3K inhibitors, promotes growth inhibitory effects in oral cancer cells, Cancer Chemother. Pharmacol. 83 (2019) 451–461; https://doi.org/10.1007/s00280-018-3746-x30519710
- 24. A. Narayanankutty, Phytochemicals as PI3K/Akt/mTOR inhibitors and their role in breast cancer treatment, Recent Pat. Anticancer Drug Discov. 15(3) (2020) 188–199; https://doi.org/10.2174/157489281566620091016464132914720
- 25. J. H. Lin, P. C. Ting, W. S. Lee, H. W. Chiu, C. A. Chien, C. H. Liu, L. Y. Sun and K. T. Yang, Palmitic acid methyl ester induces G2/M arrest in human bone marrow-derived mesenchymal stem cells via the p53/p21 pathway, Stem Cells Int. 2019 (2019) Article ID 7606238 (16 pages); https://doi.org/10.1155/2019/7606238691501231885624
- 26. X. Yin, R. Zhang, C. Feng, J. Zhang, D. Liu, K. Xu, X. Wang, S. Zhang, Z. Li, X. Liu and H. Ma, Diallyl disulfide induces G2/M arrest and promotes apoptosis through the p53/p21 and MEK-ERK pathways in human esophageal squamous cell carcinoma, Oncol. Rep. 32(4) (2014) 1748–1756; https://doi.org/10.3892/or.2014.336125175641
- 27. M. Saleem, J. Asif, M. Asif and U. Saleem, Amygdalin from apricot kernels induces apoptosis and causes cell cycle arrest in cancer cells: an updated review, Anticancer Agents Med. Chem. 18(12) (2018) 1650–1655; https://doi.org/10.2174/187152061866618010516113629308747
- 28. Y. Li, Y. Zhou, M. Wang, X. Lin, Y. Zhang, I. Laurent, Y. Zhong and J. Li, Ampelopsin inhibits breast cancer cell growth through mitochondrial apoptosis pathway, Biol. Pharm. Bull. 44(11) (2021) 1738–1745; https://doi.org/10.1248/bpb.b21-0047034470980
- 29. M. B. Kastan and J. Bartek, Cell-cycle checkpoints and cancer, Nature 432 (2004) 316–323; https://doi.org/10.1038/nature0309715549093
- 30. Y. Sun, Y. Liu, X. Ma and H. Hu, The influence of cell cycle regulation on chemotherapy, Int. J. Mol. Sci. 22(13) (2021) Article ID 6923 (25 pages); https://doi.org/10.3390/ijms22136923826772734203270
- 31. V. M. Dirsch, D. S. Antlsperger, H. Hentze and A. M. Vollmar, Ajoene, an experimental anti-leukemic drug: mechanism of cell death, Leukemia 16 (2002) 74–83; https://doi.org/10.1038/sj.leu.240233711840266
- 32. S. Wullschleger, R. Loewith and M. N. Hall, TOR signaling in growth and metabolism, Cell 124(3) (2006) 471–484; https://doi.org/10.1016/j.cell.2006.01.01616469695
- 33. J. H. Kim, C. Xu, Y. S. Keum, B. Reddy, A. Conney and A. N. Kong, Inhibition of EGFR signaling in human prostate cancer PC-3 cells by combination treatment with beta-phenylethyl isothiocya-nate and curcumin, Carcinogenesis 27(3) (2006) 475–482; https://doi.org/10.1093/carcin/bgi27216299382
- 34. R. Rong and X. Xijun, Erythropoietin pretreatment suppresses inflammation by activating the PI3K/Akt signaling pathway in myocardial ischemia-reperfusion injury, Exp. Ther. Med. 10(2) (2015) 413–418; https://doi.org/10.3892/etm.2015.2534450942326622330
- 35. G. Hoxhaj and B. D. Manning, The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolismo, Nat. Rev. Cancer 20 (2020) 74–88; https://doi.org/10.1038/s41568-019-0216-7731431231686003
- 36. N. Lamm, S. Rogers and A. J. Cesare, The mTOR pathway: implications for DNA replication, Prog. Biophys. Mol. Biol. 147 (2019) 17–25; https://doi.org/10.1016/j.pbiomolbio.2019.04.00230991055
- 37. L. Chen and H. Wang, Nicotine promotes human papillomavirus (HPV)-immortalized cervical epithelial cells (H8) proliferation by activating RPS27a-Mdm2-P53 pathway in vitro, Toxicol. Sci. 167(2) (2019) 408–418; https://doi.org/10.1093/toxsci/kfy24630272249
- 38. L. Liu, W. Michowski, A. Kolodziejczyk and P. Sicinski, The cell cycle in stem cell proliferation, pluripotency and differentiation, Nat. Cell Biol. 21 (2019) 1060–1067; https://doi.org/10.1038/s41556-019-0384-4706570731481793
- 39. H. K. Matthews, C. Bertoli and R. de Bruin, Cell cycle control in cancer, Nat. Rev. Mol. Cell Biol. 23 (2022) 74–88; https://doi.org/10.1038/s41580-021-00404-334508254
- 40. B. Xie, S. Wang, N. Jiang and J. J. Li, Cyclin B1/CDK1-regulated mitochondrial bioenergetics in cell cycle progression and tumor resistance, Cancer Lett. 443 (2019) 56–66; https://doi.org/10.1016/j.canlet.2018.11.019675906130481564
- 41. W. Lin, J. Xie, N. Xu, L. Huang, A. Xu, H. Li, C. Li, Y. Gao, M. Watanabe, C. Liu and P. Huang, Glaucocalyxin A induces G2/M cell cycle arrest and apoptosis through the PI3K/Akt pathway in human bladder cancer cells, Int. J. Biol. Sci. 14(4) (2018) 418–426; https://doi.org/10.7150/ijbs.23602593047429725263
- 42. M. Wasner, K. Tschöp, K. Spiesbach, U. Haugwitz, C. Johne, J. Mössner, R. Mantovani and K. Engeland, Cyclin B1 transcription is enhanced by the p300 coactivator and regulated during the cell cycle by a CHR-dependent repression mechanism, FEBS Lett. 536(1–3) (2003) 66–70; https://doi.org/10.1016/s0014-5793(03)00028-012586340
- 43. X. Q. Wang, C. M. Lo, L. Chen, E. S. Ngan, A. Xu and R. Y. Poon, CDK1-PDK1-PI3K/Akt signaling pathway regulates embryonic and induced pluripotency, Cell Death Differ. 24 (2017) 38–48; https://doi.org/10.1038/cdd.2016.84526050527636107